Antitumor activity of an enzyme prodrug therapy targeted to the breast tumor vasculature

Brent D. Van Rite; John J. Krais; Mohamad Cherry; Vassilios I. Sikavitsas; Carla Kurkjian; Roger G. Harrison

doi:10.3109/07357907.2013.840383

Antitumor activity of an enzyme prodrug therapy targeted to the breast tumor vasculature

Brent D. Van Rite, John J. Krais, Mohamad Cherry, Vassilios I. Sikavitsas, Carla Kurkjian, Roger G. Harrison

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

The L-methioninase-annexin V/selenomethionine enzyme prodrug system, designed to target the tumor vasculature and release the methylselenol anticancer drug in the tumor, was tested in mice with implanted MBA-MB-231 breast tumors. This therapy was able to cause a reduction in the size of the tumors during the treatment period. It was shown that L-methioninase-annexin V was uniformly bound at the blood vessel surface in the tumor and also that there was a substantial cutoff of blood flowing through the treated tumor, consistent with the therapy's design. This new approach for enzyme prodrug therapy of breast cancer appears promising.

Original language	English
Pages (from-to)	505-510
Number of pages	6
Journal	Cancer Investigation
Volume	31
Issue number	8
DOIs	https://doi.org/10.3109/07357907.2013.840383
State	Published - Oct 2013

Keywords

Biochemical markers
Breast cancers
Chemotherapy
Therapy

Access to Document

10.3109/07357907.2013.840383

Cite this

@article{4bf1e9ecffd74673812d961996498638,

title = "Antitumor activity of an enzyme prodrug therapy targeted to the breast tumor vasculature",

abstract = "The L-methioninase-annexin V/selenomethionine enzyme prodrug system, designed to target the tumor vasculature and release the methylselenol anticancer drug in the tumor, was tested in mice with implanted MBA-MB-231 breast tumors. This therapy was able to cause a reduction in the size of the tumors during the treatment period. It was shown that L-methioninase-annexin V was uniformly bound at the blood vessel surface in the tumor and also that there was a substantial cutoff of blood flowing through the treated tumor, consistent with the therapy's design. This new approach for enzyme prodrug therapy of breast cancer appears promising.",

keywords = "Biochemical markers, Breast cancers, Chemotherapy, Therapy",

author = "{Van Rite}, {Brent D.} and Krais, {John J.} and Mohamad Cherry and Sikavitsas, {Vassilios I.} and Carla Kurkjian and Harrison, {Roger G.}",

note = "Funding Information: This study was supported by a grant from the Department of Defense Breast Cancer Research Program (Idea Award W81XWH-08-1-0722). Brent Van Rite was partially supported by the U.S. Department of Education Graduate Assistance in Areas of National Need Program. John Krais was supported by a grant from the Oklahoma Center for the Application of Science and Technology Health Research Program (HR11-210).",

year = "2013",

month = oct,

doi = "10.3109/07357907.2013.840383",

language = "English",

volume = "31",

pages = "505--510",

journal = "Cancer Investigation",

issn = "0735-7907",

number = "8",

}

TY - JOUR

T1 - Antitumor activity of an enzyme prodrug therapy targeted to the breast tumor vasculature

AU - Van Rite, Brent D.

AU - Krais, John J.

AU - Cherry, Mohamad

AU - Sikavitsas, Vassilios I.

AU - Kurkjian, Carla

AU - Harrison, Roger G.

N1 - Funding Information: This study was supported by a grant from the Department of Defense Breast Cancer Research Program (Idea Award W81XWH-08-1-0722). Brent Van Rite was partially supported by the U.S. Department of Education Graduate Assistance in Areas of National Need Program. John Krais was supported by a grant from the Oklahoma Center for the Application of Science and Technology Health Research Program (HR11-210).

PY - 2013/10

Y1 - 2013/10

N2 - The L-methioninase-annexin V/selenomethionine enzyme prodrug system, designed to target the tumor vasculature and release the methylselenol anticancer drug in the tumor, was tested in mice with implanted MBA-MB-231 breast tumors. This therapy was able to cause a reduction in the size of the tumors during the treatment period. It was shown that L-methioninase-annexin V was uniformly bound at the blood vessel surface in the tumor and also that there was a substantial cutoff of blood flowing through the treated tumor, consistent with the therapy's design. This new approach for enzyme prodrug therapy of breast cancer appears promising.

AB - The L-methioninase-annexin V/selenomethionine enzyme prodrug system, designed to target the tumor vasculature and release the methylselenol anticancer drug in the tumor, was tested in mice with implanted MBA-MB-231 breast tumors. This therapy was able to cause a reduction in the size of the tumors during the treatment period. It was shown that L-methioninase-annexin V was uniformly bound at the blood vessel surface in the tumor and also that there was a substantial cutoff of blood flowing through the treated tumor, consistent with the therapy's design. This new approach for enzyme prodrug therapy of breast cancer appears promising.

KW - Biochemical markers

KW - Breast cancers

KW - Chemotherapy

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84885095169&partnerID=8YFLogxK

U2 - 10.3109/07357907.2013.840383

DO - 10.3109/07357907.2013.840383

M3 - Article

C2 - 24083814

AN - SCOPUS:84885095169

SN - 0735-7907

VL - 31

SP - 505

EP - 510

JO - Cancer Investigation

JF - Cancer Investigation

IS - 8

ER -

Antitumor activity of an enzyme prodrug therapy targeted to the breast tumor vasculature

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this